Over 3 million people worldwide currently receive life-saving dialysis as a bridge to kidney transplant. Over 800,000 patients in the US with end-stage renal disease on dialysis have an average life expectancy of only 5-10 years because of the complications associated with dialysis. In the US, treatment for kidney failure consumes $34B USD or 7.1%... Read more
Nephrodite is developing Holly, a combined implantable and wearable device that represents a change in the way End-Stage Renal Disease and dialysis care is delivered. Holly is a true kidney replacement solution. One of the greatest attributes of Holly is returning autonomy to patients. Our device will offer mobility and independence to patients enj... Read more
